PFE logo

Pfizer Inc.

PFE
Healthcare|Drug Manufacturers - General|US
$29.39
-0.06 (-0.20%)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50

Financials

Financial Snapshot

Market Cap
$167.51B
Enterprise Value
$228.36B
Revenue (TTM)
$63.62B
Net Income (TTM)
$4.03B
Cash & Investments
$14.27B
Net Cash
-$48.40B
Free Cash Flow (TTM)
$11.79B
Operating CF (TTM)
$14.17B
Debt/Equity
0.70

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$17.85B$19.99B$18.83B$9.65B$12.22B$31.07B$22.73B$12.69B$20.48B$13.60B$14.27B
Operating Cash Flow
$15.90B$16.47B$15.83B$12.59B$14.40B$32.58B$29.27B$8.70B$12.74B$11.71B$14.17B
Free Cash Flow
$13.90B$14.25B$13.63B$9.99B$11.61B$29.87B$26.03B$4.79B$9.84B$9.08B$11.79B
Capital Expenditure
-$2.00B-$2.22B-$2.20B-$2.59B-$2.79B-$2.71B-$3.24B-$3.91B-$2.91B-$2.63B-$2.39B
Financing Cash Flow
-$8.92B-$13.04B-$20.44B-$8.48B-$9.65B-$9.82B-$14.83B$26.07B-$17.14B-$10.30B-$8.43B

R&D Spending

R&D (TTM)
$11.52B
R&D Intensity
18.1%
R&D Growth vs Prior
+10.4%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$52.82B$52.55B$40.83B$40.91B$41.65B$81.29B$101.17B$59.55B$63.63B$62.58B$63.62B
R&D Expense
$7.89B$7.68B$7.76B$8.38B$9.39B$13.83B$11.43B$10.68B$10.82B$10.44B$11.52B
R&D % of Revenue
14.9%14.6%19.0%20.5%22.6%17.0%11.3%17.9%17.0%16.7%18.1%
SG&A
$14.84B$14.80B$12.61B$12.73B$11.60B$12.70B$13.68B$14.77B$14.73B$13.79B$13.81B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$52.82B$52.55B$40.83B$40.91B$41.65B$81.29B$101.17B$59.55B$63.63B$62.58B$63.62B
Cost of Revenue
$12.32B$11.23B$8.99B$8.05B$8.48B$30.82B$34.34B$24.95B$17.85B$16.07B$16.94B
Gross Profit
$40.50B$41.32B$31.84B$32.85B$33.17B$50.47B$66.83B$34.60B$45.78B$46.51B$46.68B
R&D
$7.89B$7.68B$7.76B$8.38B$9.39B$13.83B$11.43B$10.68B$10.82B$10.44B$11.52B
SG&A
$14.84B$14.80B$12.61B$12.73B$11.60B$12.70B$13.68B$14.77B$14.73B$13.79B$13.81B
Operating Income
$13.71B$14.07B$6.73B$7.31B$8.83B$20.23B$38.12B$4.42B$14.94B$17.41B$15.16B
Interest Expense
$1.19B$1.27B$1.32B$1.57B$1.45B$1.29B$1.24B$2.21B$3.09B$2.67B$2.71B
Pretax Income
$8.35B$12.30B$3.59B$11.32B$7.04B$24.31B$34.73B$1.06B$8.02B$7.52B$4.26B
Net Income
$7.21B$21.31B$11.15B$16.03B$9.16B$21.98B$31.37B$2.12B$8.03B$7.77B$4.03B
EPS (Diluted)
1.173.521.872.871.633.885.470.371.411.360.70
EBITDA
$15.29B$19.84B$11.06B$18.65B$13.26B$30.79B$41.03B$9.56B$18.13B$16.78B$13.47B
Shares Out. (M)
6159.006058.005977.005675.005632.005708.005733.005709.005700.005686.005751.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$2.60B$1.34B$1.14B$1.12B$1.79B$1.94B$416.0M$2.85B$1.04B$1.14B$1.82B
Short-Term Investments
$15.26B$18.65B$17.69B$8.53B$10.44B$29.13B$22.32B$9.84B$19.43B$12.45B$12.45B
Total Current Assets
$38.95B$41.14B$49.93B$32.80B$35.07B$59.69B$51.26B$43.33B$50.36B$42.90B$45.01B
Total Assets
$171.62B$171.80B$159.42B$167.49B$154.23B$181.48B$197.21B$226.50B$213.40B$208.16B$204.54B
Total Current Liabilities
$31.11B$30.43B$31.86B$37.30B$25.92B$42.67B$42.14B$47.79B$42.99B$36.98B$31.73B
Long-Term Debt
$30.40B$32.67B$32.91B$34.65B$35.57B$34.76B$31.93B$60.50B$57.41B$61.64B$60.00B
Total Liabilities
$111.78B$100.14B$95.66B$104.15B$90.76B$104.01B$101.29B$137.21B$124.90B$121.39B$115.24B
Stockholders' Equity
$59.54B$71.31B$63.41B$63.14B$63.24B$77.20B$95.66B$89.01B$88.20B$86.48B$89.00B
Retained Earnings
$71.77B$85.29B$89.55B$97.67B$96.77B$103.39B$125.66B$118.35B$116.72B$114.61B$115.33B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$15.90B$16.47B$15.83B$12.59B$14.40B$32.58B$29.27B$8.70B$12.74B$11.71B$14.17B
Capital Expenditure
-$2.00B-$2.22B-$2.20B-$2.59B-$2.79B-$2.71B-$3.24B-$3.91B-$2.91B-$2.63B-$2.39B
Free Cash Flow
$13.90B$14.25B$13.63B$9.99B$11.61B$29.87B$26.03B$4.79B$9.84B$9.08B$11.79B
Investing Cash Flow
-$7.81B-$4.74B$4.53B-$3.94B-$4.27B-$22.55B-$15.78B-$32.28B$2.65B-$1.35B-$5.28B
Financing Cash Flow
-$8.92B-$13.04B-$20.44B-$8.48B-$9.65B-$9.82B-$14.83B$26.07B-$17.14B-$10.30B-$8.43B
Issuance of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Repurchase of Stock
-$5.00B-$5.00B-$12.20B-$8.87B$0.00$0.00-$2.00B$0.00$0.00$0.00$0.00
Net Debt Issuance
$2.61B-$941.0M-$935.0M$8.76B-$12.76B-$1.10B-$3.52B$35.95B-$7.16B-$74.0M$1.75B
Stock Based Comp.
$691.0M$840.0M$949.0M$718.0M$756.0M$1.18B$872.0M$525.0M$877.0M$799.0M$1.11B
Net Change in Cash
-$1.05B-$1.25B-$206.0M-$50.0M$475.0M$158.0M-$1.51B$2.45B-$1.81B$99.0M$480.0M

Dilution Tracker

Shares Outstanding
5700M
5-Year Share Growth
+1.0%
Stock Issuance (TTM)
$0.00
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
6159.006058.005977.005675.005632.005708.005733.005709.005700.005686.005751.00
Change vs Prior %
—-1.6%-1.3%-5.1%-0.8%1.3%0.4%-0.4%-0.2%-0.2%1.1%
Stock Issuance
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Repurchase
-$5.00B-$5.00B-$12.20B-$8.87B$0.00$0.00-$2.00B$0.00$0.00$0.00$0.00
Stock Based Comp.
$691.0M$840.0M$949.0M$718.0M$756.0M$1.18B$872.0M$525.0M$877.0M$799.0M$1.11B

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
76.7%78.6%78.0%80.3%79.6%62.1%66.1%58.1%71.9%74.3%73.4%
Operating Margin %
26.0%26.8%16.5%17.9%21.2%24.9%37.7%7.4%23.5%27.8%23.8%
Net Margin %
13.7%40.6%27.3%39.2%22.0%27.0%31.0%3.6%12.6%12.4%6.3%
EBITDA Margin %
29.0%37.8%27.1%45.6%31.8%37.9%40.6%16.0%28.5%26.8%21.2%
FCF Margin %
26.3%27.1%33.4%24.4%27.9%36.7%25.7%8.0%15.5%14.5%18.5%
ROE %
12.1%29.9%17.6%25.4%14.5%28.5%32.8%2.4%9.1%9.0%4.6%
ROA %
4.2%12.4%7.0%9.6%5.9%12.1%15.9%0.9%3.8%3.7%2.0%
ROIC %
7.9%9.3%4.9%4.7%6.4%13.3%21.8%2.3%8.4%10.0%8.3%
R&D / Revenue %
14.9%14.6%19.0%20.5%22.6%17.0%11.3%17.9%17.0%16.7%18.1%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
8.1%-0.5%-22.3%0.2%1.8%95.2%24.5%-41.1%6.8%-1.6%
Gross Profit
3.3%2.0%-22.9%3.2%1.0%52.2%32.4%-48.2%32.3%1.6%
Operating Income
5.7%2.6%-52.2%8.6%20.8%129.2%88.4%-88.4%238.2%16.5%
Net Income
3.7%195.3%-47.7%43.7%-42.8%140.0%42.7%-93.2%279.0%-3.2%
EPS (Diluted)
5.1%200.6%-46.9%53.7%-43.3%138.6%41.0%-93.2%279.8%-3.5%
Operating Cash Flow
9.6%3.6%-3.9%-20.5%14.4%126.2%-10.2%-70.3%46.5%-8.2%
Free Cash Flow
6.8%2.5%-4.4%-26.7%16.2%157.2%-12.8%-81.6%105.2%-7.7%
R&D Expense
2.6%-2.6%1.0%8.1%12.0%47.2%-17.4%-6.6%1.3%-3.6%
SG&A Expense
0.2%-0.3%-14.8%0.9%-8.9%9.5%7.7%8.0%-0.3%-6.4%
Total Assets
2.5%0.1%-7.2%5.1%-7.9%17.7%8.7%14.9%-5.8%-2.5%
Book Value / Share
-6.7%22.1%-9.5%4.8%0.5%21.0%23.7%-7.5%-1.3%-2.3%
Debt
5.6%3.8%-2.0%21.8%-24.7%-3.3%-5.8%103.2%-5.4%0.6%
Diluted Shares
-1.6%-1.6%-1.3%-5.1%-0.8%1.3%0.4%-0.4%-0.2%-0.2%

Valuation

P/E (TTM)41.58
10Y Low / Med / High9.16 / 18.68 / 76.67
P/S2.63
10Y Low / Med / High2.26 / 3.90 / 5.95
P/B1.88
10Y Low / Med / High1.64 / 3.15 / 4.28
EV/EBITDA16.96
10Y Low / Med / High7.84 / 13.76 / 25.64
EV/Revenue3.59
10Y Low / Med / High3.18 / 4.50 / 6.95
P/FCF14.21
10Y Low / Med / High11.04 / 15.59 / 33.90

Intrinsic Value Models (per share)

DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
26.099.6221.7912.7122.3314.939.1676.6718.6818.3141.58
P/S Ratio
3.553.905.955.064.914.072.842.732.362.262.63
P/B Ratio
3.152.873.833.283.234.283.001.831.701.641.88
EV/EBITDA
14.7712.4125.6413.7618.1711.887.8424.1111.9312.3816.96
EV/Revenue
4.284.696.956.275.794.503.183.873.403.323.59

Analyst Estimates & Quality

Altman Z-Score
2.16
Grey Zone
Piotroski F-Score
7
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$63.02B$60.63B$55.24B
Net Income$17.35B$16.74B$14.43B
EPS$3.03$2.94$2.48
# Analysts (EPS)13137

Dividends

Dividend/Share (TTM)
$1.72
Dividend Yield
5.85%
Frequency
Quarterly
Next Payment
Dec 7, 2026

Recent Payments

Ex-DatePay DateAmountFrequency
Nov 6, 2026Dec 7, 2026$0.43Quarterly
Jul 24, 2026Sep 1, 2026$0.43Quarterly
May 8, 2026Jun 12, 2026$0.43Quarterly
Jan 23, 2026Mar 6, 2026$0.43Quarterly
Nov 7, 2025Dec 1, 2025$0.43Quarterly
Jul 25, 2025Sep 2, 2025$0.43Quarterly
May 9, 2025Jun 13, 2025$0.43Quarterly
Jan 24, 2025Mar 7, 2025$0.43Quarterly
Nov 8, 2024Dec 2, 2024$0.42Quarterly
Jul 26, 2024Sep 3, 2024$0.42Quarterly
May 9, 2024Jun 14, 2024$0.42Quarterly
Jan 25, 2024Mar 1, 2024$0.42Quarterly
Nov 9, 2023Dec 4, 2023$0.41Quarterly
Jul 27, 2023Sep 5, 2023$0.41Quarterly
May 11, 2023Jun 9, 2023$0.41Quarterly
Jan 26, 2023Mar 3, 2023$0.41Quarterly
Nov 3, 2022Dec 5, 2022$0.40Quarterly
Jul 28, 2022Sep 6, 2022$0.40Quarterly
May 12, 2022Jun 10, 2022$0.40Quarterly
Jan 27, 2022Mar 4, 2022$0.40Quarterly

Revenue Segments

By Product

Segment201920212022202320242025
Biopharma Segment$39.42B$79.56B$98.99B$57.19B$62.40B$61.20B
Upjohn Segment$10.23B—————
Business Innovation Segment———$1.31B——
Segment Reporting, Reconciling Item, Corporate Nonsegment—————$1.38B

By Geography

Segment202020212022202320242025
Developed Europe$7.79B$18.34B$21.98B$11.65B——
Developed Rest Of World$4.04B$12.51B$15.78B$7.76B$16.06B$16.19B
Emerging Markets$8.37B$20.70B$20.10B$12.00B$8.88B$9.31B
UNITED STATES$21.71B$29.75B$42.47B$27.09B$38.69B$37.08B